Apmonia Therapeutics Secures $20M Series A Funding to Accelerate Breakthrough Anti-Cancer Immunotherapy Innovation

Apmonia Therapeutics SAS is thrilled to announce the successful raise of €20,000,000 in our latest funding round, marking a significant milestone in our mission to redefine cancer treatment through innovative immunotherapy strategies. As a pioneering biotechnology company specializing in anti-cancer therapies, our dedicated research team has developed a revolutionary approach that targets tumors overexpressing the matricellular protein thrombospondin-1 (TSP-1). The recent investment will accelerate our efforts to advance the development of the proprietary TAX2 peptide, specifically designed to target TSP-1, presenting a promising new avenue in the fight against cancer. This fresh capital infusion is earmarked for scaling our research and clinical development operations while enhancing our companion diagnostic kit. The diagnostic kit is a critical component of our long-term vision for personalized medicine—it will enable precise patient stratification by monitoring circulating TSP-1 levels, ensuring that those most likely to benefit from TAX2 therapy can be accurately identified and enrolled in clinical studies. With this strategic investment, Apmonia Therapeutics is poised to evolve from promising research into transformative treatments, bridging the gap between groundbreaking science and accessible, effective cancer care. The funding not only underscores investor confidence in our innovative technological approach but also propels us closer to delivering targeted immunotherapy solutions that could change the landscape of cancer treatment. As we embark on this exciting next phase, we remain committed to advancing personalized immunotherapy and improving outcomes for patients globally, reaffirming our dedication to fighting cancer at its molecular roots.